COMMUNIQUÉS West-GlobeNewswire

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
07/05/2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to [...]
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
07/05/2025
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for [...]
Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference
07/05/2025
SYDNEY, May 07, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology [...]
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
07/05/2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]
Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*
07/05/2025
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces [...]
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
07/05/2025
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher Edinburgh, UK, 7 May 2025 - Trogenix Ltd (“Trogenix”), a pioneering [...]
Valitor Presents Multiple Preclinical Datasets on the Potential of its Innovative Anti-VEGF Therapy Dosed Twice Yearly for Wet AMD at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
07/05/2025
-VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice-yearly, as compared to every eight to twelve weeks for standard-of-care anti-VEGFs -VLTR-559 shown to be [...]
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology
07/05/2025
Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today [...]
Counslr Partners with Sack the Stigma to Expand Mental Health Wellness Resources
07/05/2025
Launch Coincides with Mental Health Awareness Month to Amplify Focus on Mental Well-being NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Counslr, a leading digital mental health company , and Sack the Stigma, a mental [...]
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
07/05/2025
PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in [...]
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
07/05/2025
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate [...]
Erasca to Present at the Bank of America Securities Health Care Conference
07/05/2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
07/05/2025
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
07/05/2025
SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
CorVista Health Announces European Respiratory Journal Publication Detailing Validation of its Non-Invasive Test for Pulmonary Hypertension
07/05/2025
Data demonstrates CorVista’s proprietary machine-learned algorithm detects elevated mean pulmonary artery pressure (mPAP) with strong sensitivity and specificity across diverse patient populations BETHESDA, Md., May 07 [...]
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
07/05/2025
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical [...]
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
07/05/2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
07/05/2025
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One [...]
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
07/05/2025
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, [...]

Pages